These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21884660)

  • 1. [5-aminosalicylic acid for induction of remission or clinical response in Crohn's disease--a survey of a Cochrane review].
    Bjerrum JT; Munck LK; Nielsen OH
    Ugeskr Laeger; 2011 Aug; 173(35):2110-3. PubMed ID: 21884660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
    Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
    Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
    Feagan BG
    Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis.
    Ford AC; Khan KJ; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Mar; 106(3):413-20. PubMed ID: 20717106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.
    Akobeng AK; Gardener E
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003715. PubMed ID: 15674913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE; Hanauer SB
    Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: maintenance treatment of Crohn's disease.
    Biancone L; Tosti C; Fina D; Fantini M; De Nigris F; Geremia A; Pallone F
    Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():31-7. PubMed ID: 12786610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effects of 5-aminosalicylic acid preparations in Crohn disease].
    Fleig WE
    Med Klin (Munich); 1999 Feb; 94 Suppl 1():22-5. PubMed ID: 10194944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 5-aminosalicylates for the maintenance of remission in Crohn's disease.
    Akobeng AK
    Am J Gastroenterol; 2011 Oct; 106(10):1857; author reply 1857-8. PubMed ID: 21979212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.